Wednesday, 10 April 2019

Levetiracetam

Common indications

  1. Seizure prophylaxis in epilepsy. Epilepsy is classified by seizure type which, in turn, guides antiepileptic drug choice. Levetiracetam is an option for monotherapy or add-on therapy of focal seizures (with or without secondary generalisation) if carbamazepine or lamotrigine are unsuitable or not tolerated. It may be used for add-on therapy for myoclonic seizures and generalised tonic–clonic seizures if the first agent is insufficient.
  2. Selected cases of established convulsive status epilepticus that have not responded to adequate treatment with a benzodiazepine.

 

Mechanisms of action

  • The molecular target of levetiracetam is synaptic vesicle protein 2A (SV2A)
  • SV2A is expressed throughout the brain, in both excitatory and inhibitory synapses, as a glycoprotein located within the membranes of synaptic vesicles. Synaptic vesicles are where neurotransmitters are stored in the presynaptic nerve terminal. 
  • During depolarisation, synaptic vesicles fuse with the pre-synaptic membrane to release neurotransmitters into the synaptic cleft. 
  • It is presumably through interfering with synaptic vesicle function that levetiracetam modulates neuronal excitability and reduces the risk of seizures. 
  • The intermediate steps in this mechanism are, however, poorly understood.

 

Important adverse effects

  • In comparison with many other antiepileptic drugs, levetiracetam is generally well tolerated. Most patients have only mild adverse effects, or none at all. 
  • Drowsiness (affecting about 10), weakness, dizziness and headache are the most common adverse effects. 
  • Mood disturbance and psychiatric adverse effects are less common (about 5% and 2.5%, respectively), but more likely to cause discontinuation. 
  • Suicidal ideation and serious hypersensitivity reactions have been reported rarely.

 

Warnings

  • Levetiracetam is eliminated by the kidneys, so dosage reduction may be required in renal impairment. 
  • There is no evidence that levetiracetam increases the overall risk of congenital malformation when taken during pregnancy, although it is difficult to exclude effects on specific congenital defects.

 

Important interactions

  • In contrast to many other antiepileptic drugs, levetiracetam has few clinically significant interactions, and this is one of its major advantages. 
  • In particular, it does not have important interactions with other antiepileptic drugs, hormonal contraception, or warfarin.

No comments:

Post a Comment